The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization
Abstract
Purpose Fibrovascular scar formation related to subfoveal type 2 choroidal neovascularization (CNV) often causes severe vision loss in eyes with age-related macular degeneration. The authors assessed additional impacts of intravitreal tissue plasminogen activator (tPA), a fibrinolytic compound, combined with intravitreal ranibizumab (IVR) on subfoveal type 2 CNV. Methods Eight eyes of eight patients with type 2 CNV underwent intravitreal injections of ranibizumab and tPA (IVR/tPA) (40 kIU). Twelve eyes of 12 patients with type 2 CNV were treated with only IVR injections, as the control group. For retreatment, IVR was performed as needed. The best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) and macular volume (MV) on optical coherence tomography were recorded periodically for 6 months. Results The subretinal fibrinous and fibrovascular tissue complex regressed or contracted immediately after administration of IVR/tPA in contrast to IVR monotherapy. The total numbers of IVR injections did not differ significantly between the two groups. The mean logarithm of the minimum angle of resolution BCVA in the combination therapy group improved significantly from 0.72 at baseline to 0.51 at month 6 and was superior to that in the monotherapy group (0.70-0.79). The improvements of the mean CRT and MV in the combination therapy group were superior to the monotherapy group. No tPA-related complications developed. Conclusions tPA may have a specific ability to reg…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reports on macular atrophy as a result of nAMD have not distinguished atrophy associated with fibrotic scar from macular atrophy without any pre-existing fibrosis.5,10, 33-35”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [35]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationFriedman, D. S. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.7.1019 · Cited by 656
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Brown, D., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., & Kim, R. Y. (2006) · Cited by 382
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361 · cited 1×
“However, subgroup analysis of the ANCHOR study showed that the VA decreased in some eyes despite suppressed CNV activity after monthly IVR in association with larger CNV lesions at baseline and post-treatment formation of atrophic scars and pigmentary abnormalities [8, 9].”
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335 · cited 2×
“Scarring is more likely to develop in eyes with type 2 CNV and a subfoveal tissue complex [12].”
Comparison of Age-related Macular Degeneration Treatments Trials Research, G. (2011) · doi:10.1056/nejmicm1005605 · Cited by 273
Cited by
Daniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
Baek, J., Kim, J. H., Lee, M. Y., & Lee, W. K. (2017) · Retina · doi:10.1097/iae.0000000000001817 · Cited by 17
Ozone, D., Mizutani, T., Nozaki, M., Ohbayashi, M., Hasegawa, N., Kato, A., Yasukawa, T., & Ogura, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19617 · Cited by 12
“, Tokyo, Japan) in eyes with subfoveal type 2 CNV secondary to exudative AMD and confirmed prompt, marked regression of fibrinous tissue and contraction of the fibrovascular tissue complex with additional tPA injections.(22) However, it is”
BackgroundSelf-citationArai, K.-I., Yasukawa, T., Kato, A., Kubota, A., Usui, H., Takase, N., Kuwayama, S., & Ogura, Y. (2018) · Ophthalmic Research · doi:10.1159/000487054 · Cited by 6
Self-citationMacular hole and serous pigment epithelial detachment in bilateral acquired vitelliform lesions
Yata, N., Yasukawa, T., Kawamura, M., Hirano, Y., & Ogura, Y. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100628 · Cited by 2
“We previously reported the effect of IVR/tPA on fibrinous and fibrous subretinal hyperreflective material.(14) In the current case, the AVLs in the right eye started to resolve immediately after IVR/tPA.”
Self-citation
Metadata
- Authors
- Kachi, I., Yasukawa, T., Kato, A., Takase, N., Morita, H., Kubota, A., Hirano, Y., Uemura, A., & Ogura, Y.
- Affiliations
- Nagoya City University (JP)
- Corresponding author
- Yasukawa, Tsutomu
- ORCID
- Venue
- Japanese Journal of Ophthalmology
- Published
- 2016-02-26
- Volume
- 60
- Issue
- 3
- Pages
- 179-186
- ISSN
- 0021-5155 (ISSN-L)
- 1613-2246
- OpenAlex
- W2283167537
- Cited by
- 6
- References
- 25
- Citations by year
- 2024: 1 · 2020: 1 · 2018: 2 · 2017: 1 · 2016: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Japanese Journal of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The Research Committee on Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health and Welfare of Japan
- Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of Science and a Grant-in Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan (25462758)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- tissue plasminogen activator, ranibizumab, combination therapy, intravitreal injection, thrombolysis, anti-VEGF therapy, age-related macular degeneration, visual acuity, macular volume, central retinal thickness
- MeSH terms
- Ranibizumab, Aged, Drug Therapy, Combination, Female, Fibrinolytic Agents, Fovea Centralis, Humans, Male, Tissue Plasminogen Activator, Visual Acuity, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. https://app.cochat.ai/papers/10.1007/s10384-016-0434-4
- The paper
- Kachi, I., Yasukawa, T., Kato, A., Takase, N., Morita, H., Kubota, A., Hirano, Y., Uemura, A., & Ogura, Y. (2016). Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-016-0434-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.